Volume 13 Supplement 1
First-pass and high-resolution ECG-gated MRA of the thoracic vasculature in children and adolescents using gadobutrol at 3 T
© Dabir et al; licensee BioMed Central Ltd. 2011
Published: 2 February 2011
Using first-pass MRA (FP-MRA) spatial resolution is limited by breath-hold duration, and image quality (IQ) may be hampered by motion artefacts. Studies at 1.5 T have shown that the use of blood-pool contrast agents (BP-CA) allows for motion-compensated high-resolution MRA during the steady-state, yielding significantly higher IQ compared to FP-MRA. However, MRA with BP-CAs does not allow for viability imaging. At 3 T the use of a slowly injected extracellular CA at double dose may allow for a high-resolution MRA (HR-MRA) AND viability imaging.
The purpose of this study was 1) to implement an ECG-gated free breathhing HR-MRA protocol using an extracellular CA (Gadobutrol) at 3 T and 2) to compare the vessel sharpness and image quality of standard FP-MRA to HR-MRA of the thoracic vasculature in children and adolescents with congenital disorders (CD) or acquired disease (AD) of the thoracic vasculature.
To date, 13 Patients (age range: 5 to 41 years) with CD or AD of the thoracic vasculature underwent both, FP-MRA and HR-MRA using an extracellular CA. HR-MRA imaging was part of a comprehensive imaging protocol including viability imaging for assessment of CD and AD. Vessel sharpness of left pulmonary artery (LPA), left superior pulmonary vein (LSPV) and aorta ascendens (AA) were calculated. Furthermore, image quality was rated independently by two readers using a four point grading scale (1: no image artefacts and excellent vessel sharpness; 4) severe artefacts with poor vessel delineation).
HR-MRA of the thoracic vasculature using extracellular CA offers superior vessel sharpness and improved image quality compared to standard FP-MRA at 3 T. Thus HR-MRA may be used as an add-on to standard FP-MRA. Due to the inherent delayed data acquisition of viability imaging in combination with double dose CA regimen, HR-MRA does not require additional scanning time or contrast agent injection.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.